"which being resistive causes the terminal voltage of the cell to decrease approximately as an inverse function of the volume of the barrier. Pacemaker designers use this characteristic to permit detection of incipient 'end of life' of the pacemaker's lithium cell. Greatbatch donated funds to Houghton College in New York to create a graduate program in music. The Houghton College Center for the Arts (CFA) was designed with his donations to include a concert hall, art gallery, multi-floor gathering space, and various choir and instrumental practice rooms. It was subsequently named the Greatbatch School of Music after him. Houghton College"
"batteries, which were charged by an induction coil from the outside. It was the first pacemaker implanted in America. Implantable pacemakers constructed by engineer Wilson Greatbatch entered use in humans from April 1960 following extensive animal testing. The Greatbatch innovation varied from the earlier Swedish devices in using primary cells (mercury battery) as the energy source. The first patient lived for a further 18 months. The first use of transvenous pacing in conjunction with an implanted pacemaker was by Parsonnet in the United States, Lagergren in Sweden and Jean-Jacques Welti in France in 1962–63. The transvenous, or pervenous, procedure involved"
"one surviving for over years. The preceding implantable devices all suffered from the unreliability and short lifetime of the available primary cell technology which was mainly that of the mercury battery. In the late 1960s, several companies, including ARCO in the USA, developed isotope-powered pacemakers, but this development was overtaken by the development in 1971 of the lithium iodide cell by Wilson Greatbatch. Lithium-iodide or lithium anode cells became the standard for future pacemaker designs. A further impediment to reliability of the early devices was the diffusion of water vapour from the body fluids through the epoxy resin encapsulation affecting"
"surgery; small aortic valve dilator for use during open-heart surgery; high-speed machine to test fatigue in artificial heart valves; Teflon tracheotomy plug to aid patients with paralytic polio. Although Quinton was raised in a rural Mormon community, it wasn't until age 35 that he was baptized a member of The Church of Jesus Christ of Latter-day Saints. Wayne Quinton died of congestive heart failure, age 94, at his home in the Highlands area of Seattle, Washington. Wayne Quinton Wayne Everett Quinton (January 4, 1921 – January 22, 2015) was a developer of over 30 biomedical devices, including the Quinton catheter."
"OrganOx, a spin-out company from the University of Oxford to develop a world-first device which keeps a human liver alive outside the body. This work received the 'Consultancy of the Year' award at the British Engineering Excellence Awards and three Institution of Engineering and Technology awards. Further recent awards include a 2016 Red Dot Design Award for REVITIVE Medic, a 2014 Good Design Award for the Axis-D Injector Pen, 2013 and 2012 Red Dot Design Awards for the Revitive IX and Aerosure devices, and a Frost & Sullivan European Technology Innovation Award in the Wound Infection Diagnostic Industry for its"
"choir and taught Sunday school. Specific references: General references: Wilson Greatbatch Wilson Greatbatch (September 6, 1919 – September 27, 2011) was an American engineer and pioneering inventor. He held more than 325 patents and was a member of the National Inventors Hall of Fame and a recipient of the Lemelson–MIT Prize and the National Medal of Technology and Innovation (1990). Greatbatch was born in Buffalo, New York and attended public grade school at West Seneca High School. He entered military service and served during World War II, becoming an aviation chief radioman before receiving an honorable discharge in 1945. He"
"16, 1963 Pediatrics: An Infant’s Cause of Death: Hyaline Membrane Disease. The development of the first successful LVAD prototype device developed with Thermedics was named “Heartmate” and the Heartmate II, manufactured by a successor company Thoratec, was implanted into Vice President Dick Cheney in July 2010 During the 1980s he continued research and clinical trials on an air driven left ventricular assist device and the pneumatic implantable device which became the Heartmate device for end-stage heart failure. This was one of many individual component studies that went into the development of a heart pump. Bernhard and his staff worked to"
"complete long term clinical trial studies and eventually a subsidiary company of Thermedic’s, Thermo Cardiosystems merged with Thoratec Laboratories Corporation (Nasdaq: THOR), and obtained FDA approval in 2002 of the “Heartmate” LVAD device Thoratec Heartmate II LVAD device is used in implantation today, and was implanted in Dick Cheney in July 2010 before his heart transplant in March 2012. He died on October 29, 2018 at the age of 93. William F. Bernhard William F. Bernhard (December 11, 1924 – October 29, 2018) was an American cardiovascular surgeon, Emeritus Professor of Surgery at Harvard Medical School, and cardiovascular surgical pioneer."
"as multiple organ failure. Peter Houghton Peter Houghton (20 August 1938 – 25 November 2007) was the longest surviving artificial heart transplant patient in the UK. Houghton was implanted with a Jarvik 2000 heart pump at the John Radcliffe Hospital, Oxford, England, by professor Stephen Westaby, on 20 June 2000 owing to severe heart failure. After the operation, the left ventricular assist device worked continuously supporting his heart, breaking the previous world duration record on 11 August 2004 at 1,513 days. The record represents the survival of both the person and the artificial heart. A few individuals have lived longer"
"from a heart attack in his home in Hyde Park, Cincinnati, on December 12. He was 96 years old. Henry Heimlich Henry Judah Heimlich (; February 3, 1920 – December 17, 2016) was an American thoracic surgeon and medical researcher. He is widely credited as the inventor of the Heimlich maneuver, a technique of abdominal thrusts for stopping choking, described in ""Emergency Medicine"" in 1974. He also invented the Micro Trach portable oxygen system for ambulatory patients and the Heimlich Chest Drain Valve, or ""flutter valve"", which drains blood and air out of the chest cavity. Heimlich was born in"
"Alvan Barach Alvan Leroy Barach (1895–1977) was an American physician who made important contributions to pulmonary rehabilitation and oxygen therapy. He converted the oxygen tent into a closed system and he was among the early proponents of exercise and supplemental oxygen administration for patients with lung problems. Barach was on the faculty of the Columbia University College of Physicians and Surgeons and he was widely published, particularly on topics involving oxygen. In 1934, he published a study indicating that noble gases were not essential to sustain life. Barach wrote that he had been able to keep laboratory mice alive in"
"but for many, a lifetime on heart failure medication offers a limited existence. The advent of reliable, untethered, left ventricular assist devices (LVADs), a form of artificial heart, interested him greatly and together with Stephen Westaby at Oxford he assessed a number of patients who subsequently received the Jarvic axial impellor pump as a life-time treatment. None of these patients were suitable for transplantation. Although the series was small it was published in the Lancet. One of these patients survived for 7 years and served as an excellent ambassador for the idea of life-time treatment with an LVAD. Of course"
"which comprises an implantable part, known as the VORP, which supplies the FMT with appropriate sound signal. The implant is powered by an externally worn audio processor. Geoffrey Ball was himself one of the first patients to be implanted with the Vibrant Soundbridge and is currently a bilateral user. He is the only living person known who was implanted with a medical device to cure a chronic medical condition that he also invented. He is the author of the 2011 autobiographical book ""No More Laughing at the Deaf Boy"" (288 pages, Haymon-verlag, Innsbruck-Wein) that tells the story from his boyhood"
"the conventional dependency on anticoagulant drugs that pose life-threatening side-effect risks. One of his more recent innovations is a microfabrication method for building tiny, complex, three-dimensional models of living human organs. These ""organs-on-chips,"" which mimic complicated human organ functions, are being designed to replace traditional animal-based methods for testing of drugs and toxins. The first human organ-on-a-chip, the human ""lung-on-a-chip"", was reported in Science in 2010. Created using microchip manufacturing methods, the lung-on-a-chip is a complex three-dimensional model of a breathing lung that incorporates living human lung cells within microfluidic channels in silicone rubber. In 2012, Ingber and his team"
"Bioartificial liver device A bioartificial liver device (BAL) is an artificial extracorporeal supportive device for an individual who is suffering from acute liver failure. The first bioartificial liver device was developed by Dr. Kenneth Matsumara and was named an invention of the year by ""Time"" magazine in 2001. Liver cells obtained from an animal were used instead of developing a piece of equipment for each function of the liver. The structure and function of the first device resembles that of today's BALs. Animal liver cells are suspended in a solution and a patient's blood is processed by a semipermeable membrane"
"a leading cause of death among critically ill patients in intensive care units. Triggered by an excessive and uncontrolled response to illness or injury, MODS causes organs to dysfunction gradually over a period of weeks or even days. Of those affected, 90% of adults and 54% of children die. Conventional MODS research has entailed forcing rats and mice to endure this excruciating disease. However, the LDF is supporting the development of a technique that makes use of artificially grown human tissue. Dr Karl Wooldridge, of the University of Nottingham, and his team have created an artificial human Blood Brain Barrier"
"Lyman, and a fabrication method by Kwan-Gett that made the inside of the ventricles smooth and seamless to reduce dangerous stroke-causing blood clots. On December 2, 1982, William DeVries implanted the artificial heart into retired dentist Barney Bailey Clark (born January 21, 1921), who survived 112 days with the device, dying on March 23, 1983. Bill Schroeder became the second recipient and lived for a record 620 days. Contrary to popular belief and erroneous articles in several periodicals, the Jarvik heart was not banned for permanent use. Today, the modern version of the Jarvik 7 is known as the SynCardia"
"the market designed to effectively ventilate small children and infants. These devices played a significant role in reducing the rate of breathing-related infant mortality from 70% to 10%. The Bird Mark 7 Respirator is still in use around the world. In addition he produced the Fluid Control Device. Bird won the Lifetime Scientific Achievement Award in 1985 and received another one in September 2005. He continued to contribute to the field of pulmonary science by participating in the development of the VDR, a ventilator that permits management of the most challenging patients including ARDS, trauma and inhalation injury. In 1995,"
"Colin Murdoch Colin Albert Murdoch ONZM (6 February 1929 – 4 May 2008) was a New Zealand pharmacist and veterinarian who made a number of significant inventions, in particular the tranquilliser gun, the disposable hypodermic syringe and the child-proof medicine container. He had a total of 46 patents registered in his name. Born in Christchurch, New Zealand, in 1929, to parents Mary Kathleen and Frank William James, Murdoch displayed a talent for chemistry at a very early age. Although he struggled through his schooling years with dyslexia, Murdoch already displayed an interest in both mechanical and technical skills. At the"
"saving thousands of lives. In the early 1900s, a Dubliner named Walsh and a famous Scottish urinologist called Norman Gibbon teamed together to create the standard catheter used in hospitals today. Named after the two creators, it was called the Gibbon-Walsh catheter. The Gibbon and the Walsh catheters have been described and their advantages over other catheters shown. The Walsh catheter is particularly useful after prostatectomy for it drains the bladder without infection or clot retention. The Gibbon catheter has largely obviated the necessity of performing emergency prostatectomy. It is also very useful in cases of urethral fistula. A simple"
"keeping them alive. The three most common implantable technologies are cochlear implants, PMs, and ICDs. Cochlear implants aid in the process of hearing, and are used by more than 200,000 patients worldwide. PMs and ICDs keep people alive through the measurement of bodily voltage levels, measurement of regular and irregular heartbeats, and the delivery of electric impulses when irregularities are sensed in order to keep the person alive. There are about 3 million people worldwide with pacemakers, and each year 600,000 pacemakers are implanted. The data collected from these technologies, however, is not owned by the person whose body the"
"Peter Houghton Peter Houghton (20 August 1938 – 25 November 2007) was the longest surviving artificial heart transplant patient in the UK. Houghton was implanted with a Jarvik 2000 heart pump at the John Radcliffe Hospital, Oxford, England, by professor Stephen Westaby, on 20 June 2000 owing to severe heart failure. After the operation, the left ventricular assist device worked continuously supporting his heart, breaking the previous world duration record on 11 August 2004 at 1,513 days. The record represents the survival of both the person and the artificial heart. A few individuals have lived longer than 1,512 days but"
"by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist primarily of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010. The Company preserves small diameter human saphenous vein conduits (3mm to 6mm) for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient."
"microchips for tracking of many kinds of animals, and recently in some human implants. The U.S. Food and Drug Administration (FDA) approved use of Bioglass 8625 in humans in 1994. Bioglass 45S5, one of the most important formulations, is composed of SiO, NaO, CaO and PO. Professor Larry Hench developed Bioglass at the University of Florida in the late 1960s. He was challenged by a MASH army officer to develop a material to help regenerate bone, as many Vietnam war veterans suffered badly from bone damage, such that most of them injured in this way lost their limbs. The composition"
"days before having a fatal cerebrovascular accident. Time magazine awarded the AbioCor its Invention of the Year award in late 2001. The second patient, Tom Christerson, who was given less than a 20 percent chance of surviving 30 days at the time of his surgery, lived for 512 days after receiving the AbioCor, dying on February 7, 2003 due to the wearing out of an internal membrane of the AbioCor. An additional 12 patients had the device implanted into 2004, resulting in an average life span of less than five months among all 14 patients. In some cases the device"
"device received FDA approval for both indications, in 2001 and 2003, respectively. The trial demonstrated an 81% improvement in two-year survival among patients receiving HeartMate XVE compared to optimal medical management. In addition, a destination therapy study following the REMATCH trial demonstrated an additional 17% improvement (61% vs. 52%) in one-year survival of patients that were implanted with a VAD (HeartMate XVE), with an implication for the appropriate selection of candidates and timing of VAD implantation. A test carried out in 2001 by Dr. Eric A. Rose and REMATCH study group with patients with congestive heart failure that were ineligible"
"device. In addition, Rosenberg led the team that developed the Arrow LionHeart, the world’s first completely implantable left ventricular assist device that has been utilized in 30 patients. Devices currently in development include an implantable, wireless, heart assist pump, now in clinical trials, and a wireless total heart replacement, currently undergoing pre-clinical durability testing. He is a member of the board of trustees of the American Society for Artificial Internal Organs and serves on the editorial board of its journal. Gus Rosenberg Gerson ""Gus"" Rosenberg, Ph.D., is an American biomedical engineer. He is the Jane A. Fetter Professor of Surgery,"
"a visa to the United States. He had relatives in Los Angeles, which allowed the family to move to the United States. Ganz gained a position at Cedars-Sinai Medical Center, where he remained for the rest of his career. Ganz and Dr. Jeremy Swan first developed the idea for the pulmonary artery catheter in 1970. A balloon is placed at the end of a flexible catheter, which is inserted into the pulmonary artery. Additionally, Ganz had a role in the development of thrombolysis, in which enzymes breakdown blood clots. Ganz died of natural causes on November 11, 2009, at the"
"emotional stress. Throughout the 1960s, he collaborated with a team that included his brother, engineer Arthur Kantrowitz, on the development of a left ventricular assist device. Building on his experiments with dogs, he performed the world's second permanent partial mechanical heart implantation in a human on February 4, 1966, which was successful, though the patient died 24 hours after surgery as a result of preexisting liver disease. His second implant of a partial mechanical heart on a 63-year-old woman, on May 18, 1966, lasted 13 days, until the patient died of a stroke. During these almost two weeks after the"
"Henry Heimlich Henry Judah Heimlich (; February 3, 1920 – December 17, 2016) was an American thoracic surgeon and medical researcher. He is widely credited as the inventor of the Heimlich maneuver, a technique of abdominal thrusts for stopping choking, described in ""Emergency Medicine"" in 1974. He also invented the Micro Trach portable oxygen system for ambulatory patients and the Heimlich Chest Drain Valve, or ""flutter valve"", which drains blood and air out of the chest cavity. Heimlich was born in Wilmington, Delaware, the son of Mary (Epstein) and Philip Heimlich. His paternal grandparents were Hungarian-Jewish immigrants, and his maternal"
"many other locations outside the U.S. Pulmonx also sells the Chartis® Pulmonary Assessment System, which is a patient assessment tool used with endobronchial valves to help physicians target appropriate lung compartments for treatment. Another company, Spiration (Seattle, Washington), developed a different type of endobronchial valve and was acquired by Olympus in 2010. Endobronchial valve An endobronchial valve is an implantable medical device—a small, one-way valve, which is implanted in an airway in the pulmonary system to treat one of several lung conditions. Endobronchial valves are typically implanted using a flexible delivery catheter advanced through a bronchoscope, and thus they are"
"in March 2011, Orlando was diagnosed with congestive heart failure. He was participating in a clinical study of Life Vest, a wearable defibrillator. On May 22, the defibrillator saved his life after his heart stopped for 40 seconds. Orlando was the first participant in the study to have required the vest to deliver a shock. On April 4, 2012, Orlando received an artificial heart to extend his life while he waits for a donated biological heart. The operation, performed at the University of Rochester Medical Center, was the first such operation in Upstate New York. He received a lot of"
"bio mechanical crash engineer for General Motors, to help him design a Head And Neck Support system that would eliminate or protect against these types of injuries. Working together, their goal was to create a device that would reduce the chance of a serious injury caused by the violent movement of the unrestrained head and helmet during a crash. Dr. Hubbard created the first prototypes of the HANS Device in the late 1980s, and Downing, as a firm believer of the product he had helped to create, started wearing the untested prototype of the HANS Device during his IMSA sports"